CASI is a U.S. NASDAQ-listed biopharmaceutical company focused on developing and accelerating the launch of innovative therapeutics and pharmaceutical products in China, U.S., and throughout the world. We have offices in Rockville, Maryland, and a wholly owned subsidiary in Beijing, China through which substantially all of our operations are conducted.
CASI is dedicated to the development and delivery of high-quality pharmaceutical products and innovative therapeutics to patients worldwide while targeting the China market. We are focused on acquiring, licensing, developing and commercializing products that address areas of unmet medical need. We intend to execute our plan to become the leading platform to launch medicines in the greater China market leveraging our China-based regulatory and commercial competencies and our global drug development expertise.
We have a strong and growing product pipeline of commercially available and clinical stage drug candidates, and will continue to (i) acquire additional approved and clinical stage drug candidates through in-license and acquisitions, and (ii) explore drug candidates in preclinical development.
CASI’s product portfolio includes (i) an autologous anti-CD19 T-cell therapy investigative product (CNCT19) being developed for the treatment of B-ALL and NHL (ii) CID-103, an anti-CD38 monoclonal antibody being developed for the treatment of certain hematological malignancies; (iii) China regional rights to three U.S. Food and Drug Administration (FDA)-approved drugs (EVOMELA® (melphalan hydrochloride for injection) approved by China’s National Medical Products Administration (NMPA) for marketing in China, ZEVALIN® (ibritumomab tiuxetan) and MARQIBO® (vincristine sulfate LIPOSOME injection) approved by NMPA for registration confirmatory trials in China; and (iv) a portfolio of FDA-approved abbreviated new drug applications (ANDAs).